Riley Jennifer
Chief Strategy Officer
Riley Jennifer has filed 4 SEC Form 4 filings (4 transaction rows) across 1 company, with disclosures dating back to 2025. 4 of those filings fall inside the rolling window. Most recent filing: Aug 12, 2026.
On the most recent filing, Riley Jennifer is listed as Chief Strategy Officer at Avalo Therapeutics, Inc. Inside the rolling window, Riley Jennifer reported no open-market purchases and 1 open-market sale totaling $52K in AVTX.
Companies traded
Other insiders at AVTX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$52K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Riley Jennifer made?
Riley Jennifer has filed 4 SEC Form 4 filings (4 transaction rows) across 1 company since 2025.
Which companies does Riley Jennifer trade?
Riley Jennifer has filed SEC Form 4 disclosures for 1 company, including AVTX.
When was Riley Jennifer's most recent SEC Form 4 filing?
Riley Jennifer's most recent SEC Form 4 filing on Tracefour is dated Aug 12, 2026.
What is Riley Jennifer's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Riley Jennifer is listed as Chief Strategy Officer.
What is Riley Jennifer's total buy and sell value in the current window?
Inside the rolling retention window, Riley Jennifer bought $0 and sold $52K based on SEC Form 4 filings.
What was Riley Jennifer's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 2,655 AVTX shares on 2026-08-11, worth $52K, per SEC Form 4 filings.